Insider Buying: Immunic, Inc. (NASDAQ:IMUX) Chairman Purchases 20,000 Shares of Stock

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) Chairman Duane Nash bought 20,000 shares of the firm's stock in a transaction on Friday, June 13th. The shares were purchased at an average price of $0.83 per share, for a total transaction of $16,600.00. Following the purchase, the chairman now owns 36,032 shares in the company, valued at $29,906.56. This trade represents a 124.75% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Immunic Trading Up 1.9%

Shares of NASDAQ:IMUX traded up $0.02 during trading on Monday, reaching $0.82. The company's stock had a trading volume of 670,798 shares, compared to its average volume of 885,357. The stock has a market capitalization of $78.62 million, a PE ratio of -0.67 and a beta of 1.48. Immunic, Inc. has a 12 month low of $0.56 and a 12 month high of $2.11. The firm's 50 day simple moving average is $0.95 and its two-hundred day simple moving average is $1.04.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.25). Research analysts anticipate that Immunic, Inc. will post -0.94 EPS for the current fiscal year.

Institutional Trading of Immunic

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. 683 Capital Management LLC raised its position in Immunic by 2.2% in the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company's stock worth $700,000 after purchasing an additional 15,349 shares during the period. Bridgeway Capital Management LLC raised its holdings in shares of Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock worth $215,000 after buying an additional 22,200 shares during the period. Focus Partners Wealth lifted its stake in shares of Immunic by 1.1% during the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company's stock worth $2,168,000 after acquiring an additional 23,610 shares during the last quarter. Invesco Ltd. purchased a new position in Immunic during the 4th quarter valued at $37,000. Finally, Barclays PLC bought a new position in Immunic in the 4th quarter valued at $84,000. Hedge funds and other institutional investors own 51.82% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. William Blair restated an "outperform" rating on shares of Immunic in a research report on Friday, May 16th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Immunic in a report on Thursday, May 1st. B. Riley reiterated a "buy" rating and issued a $5.00 target price (down from $6.00) on shares of Immunic in a research report on Friday, May 23rd. Wall Street Zen cut Immunic from a "hold" rating to a "sell" rating in a report on Thursday, March 20th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Immunic in a report on Thursday, June 5th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $11.60.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.